Mylataf 50 mg, 200 mg, FC tablets
PDF Leaflet Revision Date: 11 May 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of HIV-1 infection in adults and pediatric patients u226540 kg.
Dosage (summary)
One tablet orally once daily with or without food.
Special Populations
- Elderly
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation; potential risk of neural tube defects.
Key Drug Interactions
- Dofetilide
- Metformin
- Rifampin
- Etravirine
Contraindications
- Hypersensitivity to dolutegravir
- Moderate/severe hepatic impairment
- Severe renal impairment
- HIV-1 with K65R mutation
Common side effects
- Neutropenia
- Rash
- Nausea
- Fatigue
- Renal impairment
Counselling Points
- Monitor for signs of hypersensitivity
- Regular liver function tests
- Avoid breastfeeding
- Use effective contraception in women of childbearing potential
Serious warnings
- Lactic acidosis
- Severe hepatotoxicity
- Post-treatment acute exacerbation of hepatitis B
Important Disclaimer
The Mylataf 50 mg, 200 mg, FC tablets professional information leaflet below is the property of Xixia Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
